BAL
MCID: ACT216
MIFTS: 33

Acute Leukemia of Ambiguous Lineage (BAL)

Categories: Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Leukemia of Ambiguous Lineage

MalaCards integrated aliases for Acute Leukemia of Ambiguous Lineage:

Name: Acute Leukemia of Ambiguous Lineage 54 6
Mixed Phenotype Acute Leukemia 54 74
Acute Biphenotypic Leukemia 54 74
Acute Leukemia of Indeterminate Lineage 54
Acute Leukemia of Undetermined Lineage 54
Undifferentiated Acute Leukemia 54
Acute Undifferentiated Leukemia 74
Mixed Lineage Acute Leukemia 54
Biphenotypic Acute Leukaemia 30
Biphenotypic Acute Leukemia 54
Aml with Lymphoid Markers 54
All with Myeloid Markers 54
Hybrid Acute Leukemia 54
Bal 54

Classifications:



External Ids:

Summaries for Acute Leukemia of Ambiguous Lineage

MalaCards based summary : Acute Leukemia of Ambiguous Lineage, also known as mixed phenotype acute leukemia, is related to acute biphenotypic leukemia and idiopathic acute eosinophilic pneumonia. The drugs Ofloxacin and Levofloxacin have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone.

Related Diseases for Acute Leukemia of Ambiguous Lineage

Diseases related to Acute Leukemia of Ambiguous Lineage via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 139)
# Related Disease Score Top Affiliating Genes
1 acute biphenotypic leukemia 12.6
2 idiopathic acute eosinophilic pneumonia 11.2
3 leukemia 10.6
4 acute leukemia 10.5
5 pneumonia 10.4
6 lung disease 10.4
7 mercury poisoning 10.4
8 pulmonary fibrosis 10.3
9 pulmonary fibrosis, idiopathic 10.3
10 asthma 10.3
11 bronchiolitis 10.3
12 pulmonary sarcoidosis 10.2
13 essential thrombocythemia 10.2
14 wilson disease 10.2
15 bronchiolitis obliterans 10.2
16 bronchitis 10.2
17 tumefactive multiple sclerosis 10.2
18 down syndrome 10.1
19 lymphoblastic lymphoma 10.1
20 lymphoma 10.1
21 chromosomal triplication 10.1
22 extrinsic allergic alveolitis 10.1
23 pulmonary tuberculosis 10.1
24 eosinophilic pneumonia 10.1
25 leukemia, acute myeloid 10.0
26 lymphoid leukemia 10.0
27 myeloid leukemia 10.0
28 tetraploidy 10.0
29 respiratory failure 10.0
30 hematopoietic stem cell transplantation 10.0
31 spindle cell sarcoma 10.0
32 breast cancer 10.0
33 myelofibrosis 10.0
34 myeloma, multiple 10.0
35 polycythemia vera 10.0
36 acute promyelocytic leukemia 10.0
37 leukemia, acute lymphoblastic 10.0
38 aspergillosis 10.0
39 myelodysplastic syndrome 10.0
40 arthritis 10.0
41 sinusitis 10.0
42 lymphocytic leukemia 10.0
43 sarcoma 10.0
44 pyoderma 10.0
45 acute t cell leukemia 10.0
46 monoclonal gammopathy of uncertain significance 10.0
47 pyoderma gangrenosum 10.0
48 myeloid sarcoma 10.0
49 seizure disorder 10.0
50 precursor t-cell acute lymphoblastic leukemia 10.0

Graphical network of the top 20 diseases related to Acute Leukemia of Ambiguous Lineage:



Diseases related to Acute Leukemia of Ambiguous Lineage

Symptoms & Phenotypes for Acute Leukemia of Ambiguous Lineage

Drugs & Therapeutics for Acute Leukemia of Ambiguous Lineage

Drugs for Acute Leukemia of Ambiguous Lineage (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ofloxacin Approved Phase 3 82419-36-1 4583
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 6006 143
4
Methotrexate Approved Phase 3,Phase 1,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
5
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
6
tannic acid Approved Phase 3,Phase 2 1401-55-4
7
Benzocaine Approved, Investigational Phase 3,Phase 2 94-09-7, 1994-09-7 2337
8
Tacrolimus Approved, Investigational Phase 3,Phase 2 104987-11-3 445643 439492 6473866
9
Mycophenolic acid Approved Phase 3,Phase 2 24280-93-1 446541
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
11 Cytochrome P-450 Enzyme Inhibitors Phase 3
12 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Infective Agents Phase 3,Phase 1,Phase 2,Not Applicable
14 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
15 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
16 Anti-Infective Agents, Urinary Phase 3
17 Renal Agents Phase 3
18 Antirheumatic Agents Phase 3,Phase 1,Phase 2
19 Folic Acid Antagonists Phase 3,Phase 1,Phase 2
20 Dermatologic Agents Phase 3,Phase 1,Phase 2
21 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
22 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 1,Phase 2
23 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
24 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
25 Vitamin B9 Phase 3,Phase 1,Phase 2
26 Folate Phase 3,Phase 1,Phase 2
27 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
29 Vitamin B Complex Phase 3,Phase 1,Phase 2
30 Calcineurin Inhibitors Phase 3,Phase 2
31 triamcinolone acetonide Phase 3
32 Triamcinolone diacetate Phase 3
33 Antitubercular Agents Phase 3,Phase 2
34 Triamcinolone hexacetonide Phase 3
35
Azacitidine Approved, Investigational Phase 2,Phase 1,Not Applicable 320-67-2 9444
36
Clofarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 123318-82-1 119182
37
Busulfan Approved, Investigational Phase 2,Phase 1,Not Applicable 55-98-1 2478
38
Fludarabine Approved Phase 1, Phase 2,Phase 2,Not Applicable 75607-67-9, 21679-14-1 30751
39
Cytarabine Approved, Experimental, Investigational Phase 1, Phase 2,Phase 2,Not Applicable 147-94-4, 65-46-3 6253
40
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2 24356-66-9 21704 32326
41
Sorafenib Approved, Investigational Phase 2,Phase 1,Not Applicable 284461-73-0 216239 406563
42
Hydrocortisone acetate Approved, Vet_approved Phase 2,Phase 1 50-03-3
43
Hydrocortisone Approved, Vet_approved Phase 2,Phase 1 50-23-7 5754
44
Daunorubicin Approved Phase 2,Not Applicable 20830-81-3 30323
45
Idarubicin Approved Phase 2,Phase 1 58957-92-9 42890
46
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
47
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2,Phase 1 1177-87-3
48
Ichthammol Approved Phase 2 8029-68-3
49
rituximab Approved Phase 2 174722-31-7 10201696
50
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Completed NCT01371656 Phase 3 levofloxacin
2 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Recruiting NCT01951885 Phase 3 tacrolimus;methotrexate;Mycophenolate mofetil;Methotrexate (low dose)
3 Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia Completed NCT02399917 Phase 2 Azacitidine
4 Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00990249 Phase 2 Busulfan;Clofarabine;Thymoglobulin
5 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
6 Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Recruiting NCT02135874 Phase 2 Clofarabine;Cytarabine;Dexamethasone;Idarubicin;Sorafenib Tosylate;Vincristine Sulfate
7 Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm Recruiting NCT03012672 Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride
8 GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia Recruiting NCT02799147 Phase 1, Phase 2 Fludarabine monophosphate;Busulfan;Bendamustine
9 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Recruiting NCT02220985 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Methotrexate;Mycophenolate Mofetil;Tacrolimus;Thiotepa
10 Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Recruiting NCT03267186 Phase 2 Ibrutinib
11 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting NCT02728050 Phase 1, Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride;Sorafenib Tosylate
12 Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation Recruiting NCT03683433 Phase 2 Azacitidine;Enasidenib Mesylate
13 Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Recruiting NCT02397720 Phase 2 Azacitidine
14 Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant Recruiting NCT00796068 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Treosulfan
15 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease Recruiting NCT00719888 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Thiotepa
16 Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting NCT02115295 Phase 2 Cladribine;Cytarabine;Idarubicin;Midostaurin
17 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children Active, not recruiting NCT01858740 Phase 2 Fludarabine Phosphate;Methotrexate;Tacrolimus;Thiotepa
18 Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes Active, not recruiting NCT01690520 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Thiotepa
19 Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Active, not recruiting NCT02044796 Phase 1, Phase 2 Cladribine;Cytarabine;Mitoxantrone Hydrochloride
20 Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Active, not recruiting NCT02921061 Phase 1, Phase 2 Cladribine;Cytarabine;Decitabine;Mitoxantrone Hydrochloride
21 Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01028716 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Mycophenolate Mofetil;Tacrolimus
22 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer Active, not recruiting NCT00723099 Phase 2 Cyclophosphamide;Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
23 HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Active, not recruiting NCT02793544 Phase 2 Fludarabine;Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5;Busulfan;Cyclophosphamide 50mg/kg/day IV on Days -2,-1;Cyclophosphamide 50mg/kg/day IV on Days -5,-4;Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4;Sirolimus;Mycophenolate mofetil;G-CSF;Pre-HCT Mesna on Days -6 and -5;Pre-HCT Mesna on Days -2 and -1;Pre-HCT Mesna on Days -5 and -4;Post-HCT Mesna
24 Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Not yet recruiting NCT03779854 Phase 2 Thiotepa;Fludarabine;Cyclophosphamide;Busulfan;Tacrolimus;Methotrexate
25 Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting NCT03739606 Phase 2
26 Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Suspended NCT02828358 Phase 2 Azacitidine;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Hydrocortisone Sodium Succinate;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Prednisolone;Thioguanine;Vincristine Sulfate
27 Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies Terminated NCT02419755 Phase 2 Bortezomib;Vorinostat;Mitoxantrone;Cytarabine;Methotrexate;Hydrocortisone;Peg-L-Asparaginase;Erwinia L-Asparaginase;Dexamethasone;Mercaptopurine;Doxorubicin
28 Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia Terminated NCT03195010 Phase 2
29 Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Hematologic Malignancies Withdrawn NCT03399773 Phase 2 Cyclophosphamide;Fludarabine;Thiotepa
30 Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies Withdrawn NCT02718755 Phase 2 Fludarabine;Cytarabine;Erwinase
31 Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome Completed NCT02212561 Phase 1 Selinexor;Fludarabine;Cytarabine;methotrexate/hydrocortisone/cytarabine
32 Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia Completed NCT01132573 Phase 1 entinostat;clofarabine
33 Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies Completed NCT02270788 Phase 1 Crenolanib;Sorafenib;methotrexate, hydrocortisone and cytarabine with leucovorin
34 POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Completed NCT01319864 Phase 1 Plerixafor Dose Escalation
35 AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia Completed NCT01431664 Phase 1 multikinase inhibitor AT9283
36 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
37 Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage Recruiting NCT03194932 Phase 1 Venetoclax;Cytarabine;Idarubicin;Intrathecal Triple Therapy
38 Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia Recruiting NCT02879695 Phase 1
39 S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia Recruiting NCT01925131 Phase 1 cyclophosphamide;vincristine sulfate;prednisone
40 HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Recruiting NCT03326921 Phase 1 Fludarabine Phosphate
41 Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders Recruiting NCT03198234 Phase 1
42 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT02159495 Phase 1 cyclophosphamide;Fludarabine Phosphate
43 Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation Not yet recruiting NCT03843528 Phase 1 Vorinostat;Azacitidine Injection
44 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Not yet recruiting NCT03807063 Phase 1 Rimiducid
45 Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia Terminated NCT01887587 Phase 1 MLN9708;Vincristine;Doxorubicin;Dexamethasone
46 Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated NCT01701323 Phase 1 Cytarabine;Filgrastim;Fludarabine Phosphate
47 Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia Terminated NCT00933985 Phase 1 dexrazoxane hydrochloride;doxorubicin hydrochloride;obatoclax mesylate;liposomal vincristine sulfate
48 Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR) Withdrawn NCT02578511 Phase 1 Ixazomib
49 Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed NCT01804101 Not Applicable Liposomal Cytarabine-Daunorubicin CPX-351
50 Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) Recruiting NCT03496402 Not Applicable

Search NIH Clinical Center for Acute Leukemia of Ambiguous Lineage

Genetic Tests for Acute Leukemia of Ambiguous Lineage

Genetic tests related to Acute Leukemia of Ambiguous Lineage:

# Genetic test Affiliating Genes
1 Biphenotypic Acute Leukaemia 30

Anatomical Context for Acute Leukemia of Ambiguous Lineage

MalaCards organs/tissues related to Acute Leukemia of Ambiguous Lineage:

42
Myeloid, T Cells, Bone, Bone Marrow, B Lymphoblasts, B Cells, Monocytes

Publications for Acute Leukemia of Ambiguous Lineage

Articles related to Acute Leukemia of Ambiguous Lineage:

(show top 50) (show all 66)
# Title Authors Year
1
Very rare lineage switch from acute myeloid leukemia to mixed phenotype acute leukemia, B/Myeloid, during chemotherapy with no clonal evolution. ( 30707502 )
2019
2
Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. ( 30786841 )
2019
3
Mixed Phenotype Acute Leukemia, B/Myeloid with t(9;22): Diagnostic and Therapeutic Challenges. ( 30828170 )
2019
4
Mixed-phenotype acute leukemia with t(4;11)(q21;q23) KMT2A-AFF1-rearranged. ( 30872272 )
2019
5
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. ( 29991687 )
2018
6
Rapid diagnosis of mixed phenotype acute leukemia after identifying a blood histogram abnormality. ( 30009244 )
2018
7
Mixed-phenotype acute leukemia characteristics: first report from Iran. ( 30019150 )
2018
8
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. ( 30117174 )
2018
9
Biphenotypic Acute Leukemia versus Myeloid Antigen-Positive ALL: Clinical Relevance of WHO Criteria for Mixed Phenotype Acute Leukemia. ( 30140473 )
2018
10
Lineage switch from acute myeloid leukemia to T cell/myeloid mixed phenotype acute leukemia: First report of an adult case. ( 30203419 )
2018
11
Philadelphia-positive mixed phenotype acute leukemia presenting with PML-RARα fusion transcript without t(15;17) on cytogenetic studies. ( 30310796 )
2018
12
Diagnostic challenges in T-lymphoblastic lymphoma, early T-cell precursor acute lymphoblastic leukemia or mixed phenotype acute leukemia: A case report. ( 30313079 )
2018
13
Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab. ( 30328137 )
2018
14
Mixed-phenotype acute leukemia, T/megakaryoblastic. ( 30498070 )
2018
15
Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. ( 30514800 )
2018
16
PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. ( 30530780 )
2018
17
Non-leukemic pediatric mixed phenotype acute leukemia/lymphoma: Genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma. ( 30578714 )
2018
18
Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival. ( 29223952 )
2018
19
The First Case of Non-leukemic Sarcoma Composed of Mixed-phenotype Acute Leukemia, B/myeloid, Not Otherwise Specified. ( 29269643 )
2018
20
Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. ( 29492206 )
2018
21
An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL). ( 29546454 )
2018
22
Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. ( 29550836 )
2018
23
Durable remission in a patient of mixed phenotype acute leukemia with Philadelphia chromosome-positive treated with nilotinib and lenalidomide: A case report. ( 29620650 )
2018
24
Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia. ( 28694182 )
2017
25
Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. ( 28971902 )
2017
26
A RARE CASE OF MIXED PHENOTYPE ACUTE LEUKEMIA- B/T CELL TYPE. ( 29021517 )
2017
27
Mixed-Phenotype Acute Leukemia: Diagnostic Criteria and Pitfalls. ( 29072953 )
2017
28
Philadelphia Chromosome-like Mixed-Phenotype Acute Leukemia Demonstrating P2RY8-CRLF2 Fusion and JAK1 Mutation. ( 29140408 )
2017
29
Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. ( 28099272 )
2017
30
TAF15-ZNF384 fusion gene in childhood mixed phenotype acute leukemia. ( 28279306 )
2017
31
Histoplasmosis in Pleural Effusion in a 23-Year-Old Man With Mixed-Phenotype Acute Leukemia. ( 28379418 )
2017
32
Mixed-phenotype acute leukemia: state-of-the-art of the diagnosis, classification and treatment. ( 28422191 )
2017
33
Novel Cytogenetic Findings in a Case of Mixed Phenotype Acute Leukemia within the Context of a Complex Karyotype. ( 28459703 )
2017
34
MLL-rearranged mixed phenotype acute leukemia masquerading as B-cell ALL. ( 27774846 )
2017
35
Acute Leukemia of Ambiguous Lineage in Elderly Patients - Analysis of Survival Using Surveillance Epidemiology and End Results-Medicare Database. ( 27998706 )
2016
36
A Rare Case of Extramedullary T/Myeloid Mixed Phenotype Acute Leukemia with t(1;5)(q23;q33). ( 28105379 )
2016
37
THERAPY-RELATED T/MYELOID MIXED PHENOTYPE ACUTE LEUKEMIA IN A PATIENT TREATED WITH CHEMOTHERAPY FOR CUTANEOUS DIFFUSE LARGE B CELL LYMPHOMA. ( 26986862 )
2016
38
Reversible Liver Steatosis Induced by Chemotherapy of Mixed-phenotype Acute Leukemia. ( 27086827 )
2016
39
Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stem cell transplantation versus chemotherapy alone. ( 27088964 )
2016
40
First Case of Biphenotypic/bilineal (B/myeloid, B/monocytic) Mixed Phenotype Acute Leukemia with t(9;22)(q34;q11.2);BCR-ABL1. ( 27466307 )
2016
41
CD34+ highly enriched allogeneic stem cell transplantation in a patient with mixed phenotype acute leukemia and Fusarium solani sepsis. ( 26382275 )
2016
42
Philadelphia-positive dimorphic blasts in mixed-phenotype acute leukemia with TET2 mutation. ( 26799924 )
2016
43
Mixed-phenotype acute leukemia treated with decitabine. ( 26874515 )
2016
44
Fatal Cyberlindnera fabianii fungemia in a patient with mixed phenotype acute leukemia after umbilical cord blood transplantation. ( 26879198 )
2016
45
Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. ( 26903380 )
2016
46
A rare case of acute leukemia of ambiguous lineage overexpressing C-MYC with monosomy 7 and Philadelphia chromosome. ( 26159563 )
2015
47
Novel r(2)(p25q31) cytogenetic abnormality in a pediatric patient with acute leukemia of ambiguous lineage. ( 25436969 )
2015
48
Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia. ( 26021434 )
2015
49
Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion. ( 26293203 )
2015
50
Children Diagnosed as Mixed-Phenotype Acute Leukemia Didn't Benefit from the CCLG-2008 Protocol, Retrospective Analysis from Single Center. ( 25548442 )
2015

Variations for Acute Leukemia of Ambiguous Lineage

ClinVar genetic disease variations for Acute Leukemia of Ambiguous Lineage:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 VHL NM_000551.3(VHL): c.598C> T (p.Arg200Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28940298 GRCh37 Chromosome 3, 10191605: 10191605
2 VHL NM_000551.3(VHL): c.598C> T (p.Arg200Trp) single nucleotide variant Conflicting interpretations of pathogenicity rs28940298 GRCh38 Chromosome 3, 10149921: 10149921

Expression for Acute Leukemia of Ambiguous Lineage

Search GEO for disease gene expression data for Acute Leukemia of Ambiguous Lineage.

Pathways for Acute Leukemia of Ambiguous Lineage

GO Terms for Acute Leukemia of Ambiguous Lineage

Sources for Acute Leukemia of Ambiguous Lineage

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....